Market Research Logo

Ischemic Stroke - Pipeline Review, H2 2015

Ischemic Stroke - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Ischemic Stroke - Pipeline Review, H2 2015’, provides an overview of the Ischemic Stroke’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Ischemic Stroke
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Ischemic Stroke and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Ischemic Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Ischemic Stroke pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Ischemic Stroke
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Ischemic Stroke pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Ischemic Stroke Overview
Therapeutics Development
Pipeline Products for Ischemic Stroke - Overview
Pipeline Products for Ischemic Stroke - Comparative Analysis
Ischemic Stroke - Therapeutics under Development by Companies
Ischemic Stroke - Therapeutics under Investigation by Universities/Institutes
Ischemic Stroke - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Ischemic Stroke - Products under Development by Companies
Ischemic Stroke - Products under Investigation by Universities/Institutes
Ischemic Stroke - Companies Involved in Therapeutics Development
AB Science SA
Acticor Biotech
advanceCor GmbH
Angion Biomedica Corp.
AstraZeneca Plc
Athersys, Inc.
biOasis Technologies Inc.
Biogen, Inc.
BioTime, Inc.
D-Pharm Ltd.
Daiichi Sankyo Company, Limited
DiaMedica Inc.
Digna Biotech, S.L.
Genervon Biopharmaceuticals, LLC
Glialogix, Inc.
Glucox Biotech AB
Grifols, S.A.
Huons Co., Ltd.
International Stem Cell Corporation
JN-International Medical Corporation
Laboratoires Pierre Fabre SA
Lumosa Therapeutics Co., Ltd.
MediaPharma s.r.l.
Mitsubishi Tanabe Pharma Corporation
Neuralstem, Inc.
Neurotec Pharma SL
NeuroVive Pharmaceutical AB
NoNO, Inc.
Panacea Pharmaceuticals, Inc.
Pharmicell Co., Ltd.
PhytoHealth Corporation
Remedy Pharmaceuticals, Inc.
ReNeuron Group Plc
SanBio, Inc.
Saneron CCEL Therapeutics, Inc.
Simcere Pharmaceutical Group
Stemedica Cell Technologies, Inc.
SynZyme Technologies, LLC
The International Biotechnology Center (IBC) Generium
TikoMed AB
vasopharm GmbH
Vicore Pharma AB
Virogenomics, Inc.
Ischemic Stroke - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
3K3A-APC - Drug Profile
ACT-017 - Drug Profile
alteplase biosimilar - Drug Profile
BB-3 - Drug Profile
BSc-2118 - Drug Profile
C-21 - Drug Profile
Cerecellgram-Stroke - Drug Profile
CNB-001 - Drug Profile
DB-017 - Drug Profile
DM-199 - Drug Profile
Drugs to Inhibit Sir2 Protein for Ischemic Stroke and Myocardial Infarction - Drug Profile
DS-1040 - Drug Profile
GLX-1112 - Drug Profile
glyburide - Drug Profile
GM-602 - Drug Profile
GXNPC-1 - Drug Profile
HBN-1 - Drug Profile
HU-010 - Drug Profile
Human Plasmin - Drug Profile
Human Umbilical Cord Blood Cell Therapy for Neurological and Cardiovascular Diseases - Drug Profile
ISC-hpNSC - Drug Profile
levomilnacipran hydrochloride ER - Drug Profile
LT-3001 - Drug Profile
Lysimab - Drug Profile
masitinib - Drug Profile
Memantine Nitrone - Drug Profile
Mesenchymal Stem Cells - Drug Profile
MP-124 - Drug Profile
MPHE-001A - Drug Profile
MTfp-siRNA - Drug Profile
MultiStem - Drug Profile
NA-1 - Drug Profile
natalizumab - Drug Profile
NSI-566 - Drug Profile
NTKC-005 - Drug Profile
NVP-014 - Drug Profile
NVX-208 - Drug Profile
PAN-811 - Drug Profile
Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - Drug Profile
PHN-014 - Drug Profile
Pinocembrin - Drug Profile
Polyglactin 370 for Ischemic Stroke - Drug Profile
PR-15 - Drug Profile
prasugrel hydrochloride - Drug Profile
Protein for Ischemic Stroke - Drug Profile
Protein for Ischemic Stroke - Drug Profile
Protein for Ischemic Stroke - Drug Profile
Recombinant Peptide for Ischemic Stroke - Drug Profile
Recombinant Plasmin - Drug Profile
Recombinant Protein for Ischemic Cerebral Stroke and Myocardial Ischemia - Drug Profile
Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis - Drug Profile
ReN-001 - Drug Profile
RTL-551 - Drug Profile
SB-623 - Drug Profile
SIM-071201 - Drug Profile
Small Molecule to Activate Epsilon PKC for Ischemic Stroke - Drug Profile
Small Molecule to Block Sodium Channels for Ischemic Stroke - Drug Profile
Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile
Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile
Small Molecules to Activate Glutathione Peroxidase for Ischemic Stroke and Liver Failure - Drug Profile
Small Molecules to Block Sodium and hERG Channel for Ischemic Stroke - Drug Profile
Small Molecules to Inhibit CaMKII for Ischemic Stroke - Drug Profile
Small Molecules to Inhibit Kinase for Ischemic Stroke - Drug Profile
SMTP-7 - Drug Profile
StromAb - Drug Profile
T-33 - Drug Profile
TF-0023 - Drug Profile
THR-18 - Drug Profile
ticagrelor - Drug Profile
TM-700 - Drug Profile
TPAi-14 - Drug Profile
TPAi-23 - Drug Profile
TS-01 - Drug Profile
TXA-127 - Drug Profile
TXA-302 - Drug Profile
UCCB-01144 - Drug Profile
Vaccine to Target NMDAR1 for Ischemic Stroke - Drug Profile
VACNO - Drug Profile
VAS-2870 - Drug Profile
Ischemic Stroke - Recent Pipeline Updates
Ischemic Stroke - Dormant Projects
Ischemic Stroke - Discontinued Products
Ischemic Stroke - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Ischemic Stroke, H2 2015
Number of Products under Development for Ischemic Stroke - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2015
Ischemic Stroke - Pipeline by AB Science SA, H2 2015
Ischemic Stroke - Pipeline by Acticor Biotech, H2 2015
Ischemic Stroke - Pipeline by advanceCor GmbH, H2 2015
Ischemic Stroke - Pipeline by Angion Biomedica Corp., H2 2015
Ischemic Stroke - Pipeline by AstraZeneca Plc, H2 2015
Ischemic Stroke - Pipeline by Athersys, Inc., H2 2015
Ischemic Stroke - Pipeline by biOasis Technologies Inc., H2 2015
Ischemic Stroke - Pipeline by Biogen, Inc., H2 2015
Ischemic Stroke - Pipeline by BioTime, Inc., H2 2015
Ischemic Stroke - Pipeline by D-Pharm Ltd., H2 2015
Ischemic Stroke - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Ischemic Stroke - Pipeline by DiaMedica Inc., H2 2015
Ischemic Stroke - Pipeline by Digna Biotech, S.L., H2 2015
Ischemic Stroke - Pipeline by Genervon Biopharmaceuticals, LLC, H2 2015
Ischemic Stroke - Pipeline by Glialogix, Inc., H2 2015
Ischemic Stroke - Pipeline by Glucox Biotech AB, H2 2015
Ischemic Stroke - Pipeline by Grifols, S.A., H2 2015
Ischemic Stroke - Pipeline by Huons Co., Ltd., H2 2015
Ischemic Stroke - Pipeline by International Stem Cell Corporation, H2 2015
Ischemic Stroke - Pipeline by JN-International Medical Corporation, H2 2015
Ischemic Stroke - Pipeline by Laboratoires Pierre Fabre SA, H2 2015
Ischemic Stroke - Pipeline by Lumosa Therapeutics Co., Ltd., H2 2015
Ischemic Stroke - Pipeline by MediaPharma s.r.l., H2 2015
Ischemic Stroke - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015
Ischemic Stroke - Pipeline by Neuralstem, Inc., H2 2015
Ischemic Stroke - Pipeline by Neurotec Pharma SL, H2 2015
Ischemic Stroke - Pipeline by NeuroVive Pharmaceutical AB, H2 2015
Ischemic Stroke - Pipeline by NoNO, Inc., H2 2015
Ischemic Stroke - Pipeline by Panacea Pharmaceuticals, Inc., H2 2015
Ischemic Stroke - Pipeline by Pharmicell Co., Ltd., H2 2015
Ischemic Stroke - Pipeline by PhytoHealth Corporation, H2 2015
Ischemic Stroke - Pipeline by Remedy Pharmaceuticals, Inc., H2 2015
Ischemic Stroke - Pipeline by ReNeuron Group Plc, H2 2015
Ischemic Stroke - Pipeline by SanBio, Inc., H2 2015
Ischemic Stroke - Pipeline by Saneron CCEL Therapeutics, Inc., H2 2015
Ischemic Stroke - Pipeline by Simcere Pharmaceutical Group, H2 2015
Ischemic Stroke - Pipeline by Stemedica Cell Technologies, Inc., H2 2015
Ischemic Stroke - Pipeline by SynZyme Technologies, LLC, H2 2015
Ischemic Stroke - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2015
Ischemic Stroke - Pipeline by TikoMed AB, H2 2015
Ischemic Stroke - Pipeline by vasopharm GmbH, H2 2015
Ischemic Stroke - Pipeline by Vicore Pharma AB, H2 2015
Ischemic Stroke - Pipeline by Virogenomics, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Ischemic Stroke Therapeutics - Recent Pipeline Updates, H2 2015
Ischemic Stroke - Dormant Projects, H2 2015
Ischemic Stroke - Dormant Projects (Contd..1), H2 2015
Ischemic Stroke - Dormant Projects (Contd..2), H2 2015
Ischemic Stroke - Dormant Projects (Contd..3), H2 2015
Ischemic Stroke - Dormant Projects (Contd..4), H2 2015
Ischemic Stroke - Discontinued Products, H2 2015
Ischemic Stroke - Discontinued Products (Contd..1), H2 2015
Ischemic Stroke - Discontinued Products (Contd..2), H2 2015
List of Figures
Number of Products under Development for Ischemic Stroke, H2 2015
Number of Products under Development for Ischemic Stroke - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report